⌘K
Loading ticker…
As of 2026-08-24, Phio Pharmaceuticals Corp. Common Stock (PHIO) has a 3-month relative strength percentile of 62 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 47. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.8%, relative volume 1.54×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PHIO appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $97K notional.
Held by 1 ETFs · $97K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $97K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PHIO Jan avg: 7.04% median: 5.32% win: 50% σ: 26.16% n: 4 2022-04-12 → 2026-07-31 | PHIO Feb avg: 12.93% median: 0.47% win: 50% σ: 49.33% n: 4 2022-04-12 → 2026-07-31 | PHIO Mar avg: -8.98% median: -2.95% win: 50% σ: 19.80% n: 4 2022-04-12 → 2026-07-31 | PHIO Apr avg: -8.39% median: 0.00% win: 40% σ: 39.43% n: 5 2022-04-12 → 2026-07-31 | PHIO May avg: -2.00% median: 3.55% win: 60% σ: 8.73% n: 5 2022-04-12 → 2026-07-31 | PHIO Jun avg: -3.30% median: -5.22% win: 20% σ: 12.96% n: 5 2022-04-12 → 2026-07-31 | PHIO Jul avg: -10.49% median: 0.00% win: 40% σ: 21.60% n: 5 2022-04-12 → 2026-07-31 | PHIO Aug avg: -13.63% median: -16.11% win: 0% σ: 8.00% n: 4 2022-04-12 → 2026-07-31 (current) | PHIO Sep avg: 1.30% median: 3.73% win: 50% σ: 29.27% n: 4 2022-04-12 → 2026-07-31 | PHIO Oct avg: -12.05% median: -15.48% win: 25% σ: 8.67% n: 4 2022-04-12 → 2026-07-31 | PHIO Nov avg: -21.51% median: -19.39% win: 0% σ: 13.87% n: 4 2022-04-12 → 2026-07-31 | PHIO Dec avg: -23.10% median: -23.58% win: 0% σ: 10.76% n: 4 2022-04-12 → 2026-07-31 |